We know that, for instance, Austria and Germany maybe are a couple of markets where it may be greater appetite. And we understand that, especially for these kinds of surgeries, Austria is a big center where patients already travel to the EB center.

May 15, 2025 / receipt, needs a key / Madhav, other | earnings call 2025-05-15 | transcript b02c3c62-def7-48fa-b84e-f86e9bc8bee3 | chars 32326-32574 | segment 33

That said, PZ-cell treatment, like other autologous cell and gene therapies, is an involved process that requires extensive treatment planning, travel, and care coordination.

May 15, 2025 / receipt, needs a key / Dr. Madhav Vasantavada, other | earnings call 2025-05-15 | transcript b02c3c62-def7-48fa-b84e-f86e9bc8bee3 | chars 6789-6963 | segment 6

Yeah, you've addressed most, and I would just say even within Europe, right, Ram? We'll look to see what's really the market where the reimbursement landscape also in the market access looks positive. We know that, for instance, Austria and Germany maybe are a couple of markets where it may be greater appetite. And we understand that, especially for these kinds of surgeries, Austria is a big center where patients already travel to the EB center. So from a logistics standpoint, it's not like we have to go into multiple markets, but rather already take advantage of the infrastructure and the patient pathway that exists in these kinds of markets.

Mar 20, 2025 / receipt, needs a key / Madhav, other | earnings call 2025-03-20 | transcript 445201ca-6f67-472d-a4b9-025352acfe16 | chars 32095-32746 | segment 33

I think total number, not at this point in time, we don't anticipate going more than 10. And yeah, so five this year and building it up slowly. Part of the reason is because we see that patients already in the status quo are used to traveling to centers that have specialty to be able to do multiple procedures, right? Either for infections or surgical procedures, and for various reasons, they are comfortable traveling, not for periodic application, but for these kinds of one-time, you know, important procedures.

Mar 20, 2025 / receipt, needs a key / David Bouts, analyst | earnings call 2025-03-20 | transcript 445201ca-6f67-472d-a4b9-025352acfe16 | chars 33758-34274 | segment 34

Finally, I want to mention Ediona Assist, our integrated support program designed to help eligible patients navigate their entire PZ-cell treatment journey, including travel and logistics.

Mar 20, 2025 / receipt, needs a key / Joe Vizzano, Chief Financial Officer | earnings call 2025-03-20 | transcript 445201ca-6f67-472d-a4b9-025352acfe16 | chars 11675-11863 | segment 11

Regarding enrollment in the EB101 vital trial, we remain on track for activating a second study site in the northeast to complement Stanford on the west coast in the second half of 21 Patient and physician interest in the study continues to be high, and we're observing a greater willingness to travel on what we believe is the growing percentage of the population starting to receive vaccines for COVID-19.

May 25, 2021 / receipt, needs a key / Michael Amoroso, CEO | earnings call 2021-05-25 | transcript f09400aa-33e4-4875-b2d1-151b57464140 | chars 8025-8432 | segment 7

With expansion into solid tumor oncology with ABO-701 and partnered assets, Abeona is positioned for disciplined, value-driven growth.

ir_statement / Sep 15, 2026 / receipt

With expansion into solid tumor oncology with ABO-701 and partnered assets, Abeona is positioned for disciplined, value-driven growth.

ir_statement / Sep 15, 2026 / receipt

Pipeline expansion into solid tumor oncology with PSMA program, a multi-billion-dollar opportunity

ir_statement / Sep 8, 2026 / receipt

Significant support of ZEVASKYN® from the RDEB community and commercial launch on positive trajectory

ir_statement / Sep 8, 2026 / receipt

Combination of in-house cGMP manufacturing, regulatory expertise, and a lean commercial model.

ir_statement / Sep 8, 2026 / receipt

With expansion into solid tumor oncology with ABO-701 and partnered assets,

ir_statement / Sep 8, 2026 / receipt

Published coverage policies now in place for 95% of commercially insured U.S. lives; no patient attrition and no final payer denials to date

ir_statement / Sep 8, 2026 / receipt

Pipeline expansion into solid tumor oncology with PSMA program, a multi-billion-dollar opportunity

ir_statement / Aug 30, 2026 / receipt

Significant support of ZEVASKYN® from the RDEB community and commercial launch on positive trajectory

ir_statement / Aug 30, 2026 / receipt

Combination of in-house cGMP manufacturing, regulatory expertise, and a lean commercial model.

ir_statement / Aug 30, 2026 / receipt

With expansion into solid tumor oncology with ABO-701 and partnered assets,

ir_statement / Aug 30, 2026 / receipt

Q1 26 net product revenue of $8.7M vs. Q4 25 net product revenue of $2.4M

ir_statement / Aug 30, 2026 / receipt